Market Overview

Endo Wins Citi Upgrade On Positive Catalysts, Cellulite Treatment Opportunity

Share:
Endo Wins Citi Upgrade On Positive Catalysts, Cellulite Treatment Opportunity
Related ENDP
Benzinga's Top Upgrades, Downgrades For November 9, 2018
80 Biggest Movers From Yesterday
Generics under pressure on expanded price-fixing investigation (Seeking Alpha)

Endo International PLC (NASDAQ: ENDP) is now trading at a favorable risk-reward profile and investors should be constructive on the stock, according to Citi.

The Analyst

Citi's Liav Abraham upgraded Endo International from Neutral to Buy with a price target lifted from $7 to $11.

The Thesis

Endo is an attractive stock, despite a recent rally, Abraham said in the upgrade note. (See the analyst's track record here.)  

Abraham named the following as drivers of Citi's newly bullish stance: 

  • The company's base business is underappreciated by the Street and should drive upside to estimates from its status as the exclusive distributor of Somerset's glycopyrrolate injection, which should see accelerated growth.
  • Delays in competitors like hydrocodone APAP that were expected to enter the market in the first half of 2018.
  • Execution on new launches of potential durable commercial assets.
  • Better-than-expected benefits from the acquisition of the Somerset business.

Endo's CCH cellulite opportunity represents the company's "next big opportunity" for three reasons, the analyst said:

  • The company is targeting a significant unmet need in a widespread condition.
  • Recent clinical data from Phase 2b trials of CCH in cellulite were "compelling."
  • A growing demand among patients who want non-invasive, injectable aesthetic procedures

Price Action

Endo International shares were trading down 0.11 percent at $9.16 near the end of Wednesday's session.

Related Links:

Cantor Fitzgerald: 18 Drug Companies With Catalysts Worth Watching

Endo To Enter A Year Of Recovery Following FDA Request To Pull Opana ER Off The Market

Latest Ratings for ENDP

DateFirmActionFromTo
Nov 2018Canaccord GenuityUpgradesHoldBuy
Oct 2018Cantor FitzgeraldMaintainsNeutralNeutral
Sep 2018Goldman SachsUpgradesSellNeutral

View More Analyst Ratings for ENDP
View the Latest Analyst Ratings

Posted-In: CCH Cellulite CitiAnalyst Color Upgrades Health Care Price Target Analyst Ratings General Best of Benzinga

 

Related Articles (ENDP)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
TVPTImperial CapitalDowngrades15.8
ACORGoldman SachsDowngrades10.0
APTIJefferiesDowngrades38.0
BCOVB. Riley FBRUpgrades12.0
CAMPFirst AnalysisDowngrades22.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Benzinga's Deals Of The Week For A Great Fourth Of July: Waterproof Beach Speakers, Patriotic Hammocks, And Other Summertime Gadgets

Wall Street Bets Big On World Wrestling Entertainment's Future